证券代码：301559 证券简称：中集环科 公告编号：2025-003 中集安瑞环科技股份有限公司 关于召开 2024 年年度股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 4、会议召开的日期、时间： （1）现场会议召开时间：2025 年 4 月 14 日（星期一）下午 14:30 （2）网络投票时间：2025 年 4 月 14 日，其中：①通过深圳证券交易所交 易系统进行网络投票的时间为 2025 年 4 月 14 日 9:15-9:25，9:30-11:30 和 13:00- 15:00；②通过深圳证券交易所互联网系统进行网络投票的具体时间为 2025 年 4 月 14 日 9:15-15:00。 5、会议召开方式：本次股东会采用现场表决与网络投票相结合的方式召开。 公司股东应选择现场投票、网络投票中的一种方式，如果同一表决权出现重复投 票表决的，以第一次投票表决结果为准。 6、股权登记日：2025 年 4 月 7 日（星期一） 7、出席对象： 中集安瑞环科技股份有限公司（以下简称"公司"）根据公司第二届董事会 第八次会议决议，决定于 202 ...

证券代码：301559 证券简称：中集环科 公告编号：2025-002 中集安瑞环科技股份有限公司 第二届监事会第八次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 中集安瑞环科技股份有限公司（以下简称"公司"）第二届监事会第八次会议 于 2025 年 3 月 20 日在公司会议室以现场结合通讯方式召开。会议通知于 2025 年 3 月 10 日以书面方式发出。本次会议由公司监事会主席秦钢先生主持，会议 应出席监事 3 人，实际亲自出席监事 3 人，其中监事秦钢先生、刘瑛女士以通讯 方式出席会议。 本次监事会会议的召集、召开和表决程序符合《中华人民共和国公司法》（以 下简称"《公司法》"）等有关法律法规、规范性文件和《中集安瑞环科技股份有 限公司章程》（以下简称"《公司章程》"）的规定。 二、监事会会议审议情况 经与会监事审议表决，形成决议如下： （一）审议通过《关于 2024 年度监事会工作报告的议案》 报告期内，监事会的全体成员严格按照《公司法》《公司章程》以及《监事 会议事规则》等有关规定，本着对公司及全体股东负责的 ...

证券代码：301559 证券简称：中集环科 公告编号：2025-001 中集安瑞环科技股份有限公司 第二届董事会第八次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 中集安瑞环科技股份有限公司（以下简称"公司"）第二届董事会第八次会议 于 2025 年 3 月 20 日在公司会议室以现场结合通讯方式召开。会议通知于 2025 年 3 月 10 日以书面方式发出。本次会议由公司董事长杨晓虎先生主持，会议应 出席董事 7 人，实际亲自出席董事 7 人，其中董事杨晓虎先生、赖泽侨先生、丁 莉女士、李士龙先生以通讯方式出席会议。公司监事、部分高级管理人员列席了 本次会议。 本次董事会会议的召集、召开和表决程序符合《中华人民共和国公司法》（以 下简称"《公司法》"）等有关法律法规、规范性文件和《中集安瑞环科技股份有 限公司章程》（以下简称"《公司章程》"）的规定。 二、董事会会议审议情况 经与会董事审议表决，形成决议如下： （一）审议通过《关于<2024 年度总裁工作报告>的议案》 全体与会董事认真听取并审议了公司总裁工作报告，认为 ...

中集安瑞环科技股份有限公司 关于 2024 年度利润分配预案的公告 证券代码：301559 证券简称：中集环科 公告编号：2025-004 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、中集安瑞环科技股份有限公司（以下简称"公司"）2024 年度利润分配预 案为：以截至 2024 年 12 月 31 日公司总股本 60,000 万股为基数，向全体股东每 10 股派发现金红利 4.4 元（含税），合计派发现金红利 2.64 亿元人民币（含税）， 不送红股，不以资本公积金转增股本，剩余未分配利润结转至以后年度。 2、公司利润分配预案不触及《深圳证券交易所创业板股票上市规则》第 9.4 条相关规定的可能被实施其他风险警示情形。 一、审议程序 公司于 2025 年 3 月 20 日召开第二届董事会第八次会议和第二届监事会第八 次会议，审议通过了《关于 2024 年度利润分配预案的议案》，该议案尚需提交 公司 2024 年年度股东会审议。 1、董事会审议情况 公司第二届董事会第八次会议以 7 票同意，0 票反对，0 票弃权的审议结果 通过了《关于 20 ...

Financial Performance - The company's operating revenue for 2024 was ¥3,349,092,963.01, a decrease of 28.18% compared to ¥4,663,223,578.10 in 2023 [21]. - The net profit attributable to shareholders for 2024 was ¥303,870,229.83, down 49.01% from ¥595,904,772.26 in 2023 [21]. - The net cash flow from operating activities decreased by 67.08% to ¥302,066,110.68 in 2024 from ¥917,664,410.97 in 2023 [21]. - Basic earnings per share for 2024 were ¥0.51, a decline of 54.46% compared to ¥1.12 in 2023 [21]. - The total assets at the end of 2024 were ¥5,452,806,845.37, a decrease of 2.31% from ¥5,581,938,346.00 at the end of 2023 [21]. - The net assets attributable to shareholders increased by 0.91% to ¥4,705,498,614.70 at the end of 2024 from ¥4,662,844,409.26 at the end of 2023 [21]. - The company reported a quarterly revenue of ¥994,943,499.75 in Q4 2024, with a net profit of ¥123,741,879.09 for the same quarter [24]. - The company recognized non-operating income of ¥7,546,311.68 from government subsidies in 2024, compared to ¥11,523,083.76 in 2023 [27]. - The company experienced a significant decline in return on equity, with a weighted average ROE of 6.55% in 2024, down from 18.08% in 2023 [21]. - The company reported a significant decrease in revenue from standard stainless steel liquid tanks, which fell by 35.06% to CNY 1,672,343,739.75 [57]. - The revenue from tank containers was 2,748.35 million yuan, down 32.44% year-on-year, while medical device components revenue increased by 12.88% to 240.92 million yuan [41]. Dividend Distribution - The company plans to distribute a cash dividend of 4.4 RMB per 10 shares to all shareholders, based on a total of 600,000,000 shares [3]. - The total distributable profit for the year is 970,046,813.51 RMB, with the cash dividend accounting for 100% of the profit distribution [168]. - The company has not proposed any stock dividends or capital reserve transfers for the current year [168]. - The cash dividend distribution is based on a total share capital of 600 million shares [168]. - The company will carry forward any undistributed profits to future years [168]. Research and Development - The company's R&D investment amounted to CNY 124,144,901.81, representing 3.71% of operating revenue, which remained relatively stable [55]. - Research and development (R&D) expenses for 2024 were ¥124,144,901.81, a decrease of 19.41% compared to ¥154,040,710.66 in 2023 [67]. - The R&D investment accounted for 3.71% of the operating revenue in 2024, up from 3.30% in 2023 [69]. - The company has developed 269 valid patents, including 87 invention patents, and applied for 45 new patents during the reporting period [49]. - The company completed the development of high-performance anti-wave boards, which have become a key factor in securing orders for tank containers [68]. - The company is currently developing a new generation of liquid tank containers to meet the growing market demand for electrolyte transportation [69]. Market and Industry Position - The company operates in the tank container industry, focusing on the design, manufacturing, and sales of liquid and liquefied gas logistics equipment, and is recognized as a global leader in this sector [32]. - As of January 2025, the global tank container market has a total inventory of 882,000 units, with a new production volume of 42,100 units in 2024, representing a year-on-year decline of 25.58% [33]. - The company is positioned to benefit from national policies promoting the modernization of medical equipment, with a target of increasing investment in various sectors by over 25% by 2027 [36]. - The company has established long-term relationships with major international leasing companies and chemical logistics service providers, enhancing its competitive advantage in the industry [50]. - The company maintains approximately 50% market share in the global tank container market, according to ITCO report data [103]. Governance and Compliance - All board members attended the meeting to review the annual report, ensuring accountability and transparency [3]. - The board of directors consists of 7 members, including 3 independent directors, ensuring compliance with legal and regulatory requirements [121]. - The company has established a complete asset structure with clear ownership, ensuring no asset occupation by the controlling shareholder [126]. - The company has developed a transparent performance evaluation and incentive mechanism for senior management, promoting long-term stability [122]. - The company has established a market value management system aimed at enhancing investor value and shareholder returns, approved by the board on March 20, 2025 [117]. - The company emphasizes the importance of independent directors in safeguarding the interests of all shareholders, particularly minority shareholders [156]. Environmental and Social Responsibility - The company has made significant progress in environmental protection and has been recognized as a "National Green Factory," aligning with global sustainability trends [113]. - The company has invested ¥575.41 million in environmental protection measures and paid ¥2.89 million in environmental protection tax during the reporting period [179]. - The company operates a 500m³/d acid washing wastewater treatment facility and a 120m³/d spray wastewater treatment facility, both of which are currently running normally [179]. - The company has established a dedicated hazardous waste storage facility of 1,296m², equipped with necessary safety measures and monitoring systems [179]. - The company emphasizes social responsibility through community service, environmental protection, and charitable donations [182]. Strategic Initiatives - The company is focusing on digital transformation with an operational upgrade project that has reached 78.45% completion [92]. - The company is actively involved in the development of international standards for tank containers, contributing to the establishment of safety technical requirements for liquid hazardous goods transportation [49]. - The company is exploring strategic acquisitions to bolster its technology portfolio, with a budget of 100 million allocated for potential deals [141]. - The company plans to implement a new digital platform to improve customer engagement, projected to increase customer retention by 10% [148]. - The company aims to explore new business opportunities in high-end equipment and medical imaging sectors to diversify revenue sources and strengthen its market position [106]. Risk Management - The report emphasizes the importance of risk awareness regarding future development plans and forward-looking statements [3]. - The company faces risks from macroeconomic fluctuations, including geopolitical conflicts and energy price volatility, which may negatively impact demand in the tank container industry [107]. - The company is addressing raw material price volatility, particularly steel, by maintaining strategic supplier relationships and optimizing procurement processes to mitigate cost impacts [108]. - The company is managing foreign exchange risks due to high overseas sales and USD transactions by utilizing forward foreign exchange contracts and maintaining foreign currency deposits [109].

页 次 一、非经营性资金占用及其他关联资金往来情况的专项 审核说明 1-2 二、非经营性资金占用及其他关联资金往来情况汇总表 中国杭州市钱江新城新业路 8 号 UDC 时代大厦 A 座 5-8 层、12 层、23 层 Floors5-8,12and23,Block A,UDC Times Building,No.8 Xinye Road, Qianjiang New City,Hangzhou Tel.0571-88879999 Fax.0571-88879000 www.zhcpa.cn 关于中集安瑞环科技股份有限公司 非经营性资金占用及其他关联资金往来情况的专项审核说明 中国杭州市钱江新城新业路 8 号 UDC 时代大厦 A 座 5-8 层、12 层、23 层 Floors5-8,12and23,Block A,UDC Times Building,No.8 Xinye Road，Qianjiang New City,Hangzhou Tel.0571-88879999 Fax.0571-88879000 www.zhcpa.cn 目 录 3-6 关于中集安瑞环科技股份有限公司 非经营性资金占用及其他关联 ...

中信证券股份有限公司 关于中集安瑞环科技股份有限公司部分募投项目结项并将节余募集 资金永久补充流动资金及部分募投项目调整建设期的核查意见 中信证券股份有限公司（以下简称"中信证券"、"保荐人"）作为中集安瑞环 科技股份有限公司（以下简称"中集环科"或"公司"或"甲方"）首次公开发行股票 并在深圳证券交易所创业板上市的保荐人，根据《证券发行上市保荐业务管理办 法》《深圳证券交易所创业板股票上市规则》《深圳证券交易所创业板上市公司规 范运作指引》《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监 管要求》及《深圳证券交易所上市公司自律监管指引第 13 号——保荐业务》等 有关规定，对中集环科部分募投项目结项并将节余募集资金永久补充流动资金及 部分募投项目调整建设期事项进行了审慎核查，具体情况及核查意见如下： 一、募集资金的基本情况 经中国证券监督管理委员会《关于同意中集安瑞环科技股份有限公司首次公 开发行股票注册的批复》（证监许可[2023]1317 号）同意注册，公司首次公开发 行新股 9,000 万股，每股发行价格为 24.22 元，募集资金总额为 217,980.00 万元， 扣除发行费用（不含 ...

中集安瑞环科技股份有限公司 2024 年度审计报告 中国杭州市钱江新城新业路 8 号 UDC 时代大厦 A 座 5-8 层、12 层、23 层 Floors5-8,12and23,Block A,UDC Times Building,No.8 Xinye Road, Qianjiang New City,Hangzhou Tel.0571-88879999 Fax.0571-88879000 www.zhcpa.cn 正明该审计报告 是否由具有执业许可的会计师 "注册会 您可使用手机"扫一扫"或进入 师行业统 目 | 次 | | --- | | | 页 次 | | --- | --- | | 一、审计报告 | 1-5 | | 二、财务报表 | 6-17 | | (一) 合并资产负债表 | 6-7 | | (二) 合并利润表 | 8 | | (三) 合并现金流量表 | 9 | | (四) 合并所有者权益变动表 | 10-11 | | (五) 母公司资产负债表 | 12-13 | | (六) 母公司利润表 | 14 | | (七) 母公司现金流量表 | 15 | | (八) 母公司所有者权益变动表 | 16-17 ...

www.zhcpa.cn 内部控制审计报告 中汇会审[2025]2164号 中集安瑞环科技股份有限公司全体股东: 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求,我 们审计了中集安瑞环科技股份有限公司(以下简称中集环科公司)2024年12月31日 的财务报告内部控制的有效性。 中集安瑞环科技股份有限公司 内部控制审计报告 中国杭州市钱江新城新业路 8 号 UDC 时代大厦 A 座 5-8 层、12 层、23 层 Floors5-8,12and23,Block A,UDC Times Building,No.8 Xinye Road，Qianjiang New City,Hangzhou Tel.0571-88879999 Fax.0571-88879000 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://ac.mof.gov.cn）"进行变 。 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://kg.mof.gov.cn）"进行变 一、企业对内部控制的责任 按照《企业内部控制基本规范》《企业内部控制应用指引》《企业内部控制 评价指引》的规定,建立健 ...